We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Antifungal Drug May Kill Cancer Cells

By Biotechdaily staff writers
Posted on 05 Jul 2005
A medication that has been used for about 40 years for the treatment of skin fungus has been shown to be a potential treatment for cancer, according to a team of international researchers.

The agent, called griseofulvin, has been found to suppress the growth of cancer cells in the laboratory. More...
The findings of the study was published in the June 30, 2005, online edition of the Proceedings of the [U.S.] National Academy of Sciences. The study was a collaboration between scientists at the University of California, Santa Barbara (UCSB; USA) and the School of Biosciences and Bioengineering of the Indian Institute of Technology Bombay.

"The drug has remarkably few side effects and has been used for a long time,” said Dr. Leslie Wilson, professor of biochemistry and pharmacology at UCSB. Griseofulvin is administered orally, and has been used for years to treat ringworm and other fungal skin infections.

"We discovered that it has the ability to inhibit the growth of cancer cells, in a manner that is similar to much more powerful anticancer drugs such as taxol and vinblastine,” said Dr. Wilson. "Although the anti-cancer activity is weak, it is already approved for human use and could be used along with more powerful anticancer agents as an adjuvant in cancer chemotherapy.”

The authors discovered that the drug suppresses the proliferation of cancer cells by affecting mitosis, or cell division, and mitotic spindle microtubule function. They concluded in their report, "A mild suppression of microtubule dynamics by griseofulvin in tumor cells, combined with the effects of more powerful drugs working through other mechanisms, might provide a therapeutic advantage for treatment of certain tumors.”





Related Links:
University of California, Santa Barbara
Indian Institute of Technology Bombay

Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Automated Staining Unit
RAL Stainer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.